Baihakke, Norsina S.
HRN: 23-99-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/18/2024
CEFTAZIDIME 1GM (VIAL)
09/18/2024
09/25/2024
IV
2g
OD
Sepsis; Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: BloodstreamSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes